<DOC>
	<DOC>NCT01334151</DOC>
	<brief_summary>The primary objective of this study is to assess the speed of absorption and onset of action of BIOD-105 and BIOD-107 and compare them to Humalog®.</brief_summary>
	<brief_title>Pharmacokinetic and Pharmacodynamic Properties of BIOD-105 and BIOD-107 Compared to Humalog® in Subjects With Type 1 Diabetes</brief_title>
	<detailed_description>The secondary objectives of this study are to assess other pharmacokinetic characteristics of BIOD-105 and BIOD-107 and compare those to Humalog®, to assess other pharmacodynamic characteristics of BIOD-105 and BIOD-107 and compare those to Humalog®, and to evaluate the safety and tolerability of BIOD-105 and BIOD-107 compared to Humalog®.</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 1</mesh_term>
	<mesh_term>Insulin, Globin Zinc</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Insulin Lispro</mesh_term>
	<criteria>Subjects must present with the following: 1. Body Mass Index: ≥ 18 ≤ 28 kg/m2 2. Diagnosed with type 1 diabetes mellitus for at least 1 year 3. Insulin antibody less than or equal to 10 μU/mL at screening Subjects presenting with any of the following will not be included in the study: 1. Type 2 diabetes mellitus 2. Serum Cpeptide &gt; 1.0 ng/mL 3. HbA1c &gt; 10.0% 4. History of hypersensitivity to any of the components in the study medication 5. Treatment with any other investigational drug in the last 30 days before screening visit 6. Regular smoking as assessed clinically by the Investigator.</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>July 2013</verification_date>
</DOC>